NCT00868478 - The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2012

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Milatuzumab

Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.

Trial Locations (1)

76100

RECRUITING

Kaplan Medical Center, Rehovot